TJ (presumed Shanghai Hengrui / TJ Bio) Deal History & Licensing Activity
TJ (presumed Shanghai Hengrui / TJ Bio) is a life sciences. Over the past three years, TJ (presumed Shanghai Hengrui / TJ Bio) has been involved in 1 licensing and acquisition transaction, with a primary focus on Antibodies (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Antibodies
Focus Area
Mega Deals
TJ (presumed Shanghai Hengrui / TJ Bio) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving TJ (presumed Shanghai Hengrui / TJ Bio) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| felzartamab | Biogen | Antibodies | Unknown | license | Apr 2026 |
TJ (presumed Shanghai Hengrui / TJ Bio) Pipeline Focus
Therapeutic areas and modalities where TJ (presumed Shanghai Hengrui / TJ Bio) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches TJ (presumed Shanghai Hengrui / TJ Bio)'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About TJ (presumed Shanghai Hengrui / TJ Bio) Licensing & Deal Activity
TJ (presumed Shanghai Hengrui / TJ Bio) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, TJ (presumed Shanghai Hengrui / TJ Bio) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for TJ (presumed Shanghai Hengrui / TJ Bio) include Mega Deals (2 deals and trials). In terms of modality, TJ (presumed Shanghai Hengrui / TJ Bio) has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for TJ (presumed Shanghai Hengrui / TJ Bio) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against TJ (presumed Shanghai Hengrui / TJ Bio)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.